We are encouraged by the FDA’s Fast Track designation for BIIB080, which highlights the urgent need for innovative treatments targeting tau pathology in Alzheimer’s disease,” said Priya Singhal, M.D., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback